FCF Healthcare & Life Sciences Venture Capital Monitor – USA – 04/2024 published

FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Healthcare & Life Sciences Venture Capital Monitor – USA – 04/2024”.

The Monitor is a monthly published overview of venture capital trends in the US Healthcare & Life Sciences sector.

As of the end of April 2024 we identified the following current VC trends in the United States:

  • Total Healthcare & Life Sciences funding reached EUR 11,689m
  • Biotech received 66% (including 8% via the funding of Xaira Therapeutics) of the total investment volume (EUR 7,702m) with oncology being the leading indication (28%)
  • In April the Digital Therapy Development Company Xaira Therapeutics secures the highest transaction volume with EUR 930m, followed by Metsera with EUR 322m and Cerevance with EUR 152m
  • ARCH Venture Partners (United States) is the most active investor (by deal volume), followed by RA Capital Management (United States) and F-Prime Capital (United States)

To access the full report, please click here.

By Mathias Klozenbücher und Johannes Link.